Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression.

Hdl Handle:
http://hdl.handle.net/10147/120517
Title:
Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression.
Authors:
Leonard, Brian; Taylor, David
Affiliation:
Department of Pharmacology, National University of Ireland, Galway, Ireland.
Citation:
Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression. 2010, 24 (8):1143-52 J. Psychopharmacol. (Oxford)
Journal:
Journal of psychopharmacology (Oxford, England)
Issue Date:
Aug-2010
URI:
http://hdl.handle.net/10147/120517
DOI:
10.1177/0269881109349835
PubMed ID:
20147575
Abstract:
The majority of currently marketed drugs contain a mixture of enantiomers; however, recent evidence suggests that individual enantiomers can have pharmacological properties that differ importantly from enantiomer mixtures. Escitalopram, the S-enantiomer of citalopram, displays markedly different pharmacological activity to the R-enantiomer. This review aims to evaluate whether these differences confer any significant clinical advantage for escitalopram over either citalopram or other frequently used antidepressants. Searches were conducted using PubMed and EMBASE (up to January 2009). Abstracts of the retrieved studies were reviewed independently by both authors for inclusion. Only those studies relating to depression or major depressive disorder were included. The search identified over 250 citations, of which 21 studies and 18 pooled or meta-analyses studies were deemed suitable for inclusion. These studies reveal that escitalopram has some efficacy advantage over citalopram and paroxetine, but no consistent advantage over other selective serotonin reuptake inhibitors. Escitalopram has at least comparable efficacy to available serotonin-norepinephrine reuptake inhibitors, venlafaxine XR and duloxetine, and may offer some tolerability advantages over these agents. This review suggests that the mechanistic advantages of escitalopram over citalopram translate into clinical efficacy advantages. Escitalopram may have a favourable benefit-risk ratio compared with citalopram and possibly with several other antidepressant agents.
Item Type:
Article
Language:
en
MeSH:
Citalopram; Depressive Disorder, Major; Female; Humans; Male; Meta-Analysis as Topic; Molecular Conformation; PubMed; Randomized Controlled Trials as Topic; Serotonin Uptake Inhibitors; Stereoisomerism; Treatment Outcome
ISSN:
1461-7285

Full metadata record

DC FieldValue Language
dc.contributor.authorLeonard, Brianen
dc.contributor.authorTaylor, Daviden
dc.date.accessioned2011-01-27T14:00:23Z-
dc.date.available2011-01-27T14:00:23Z-
dc.date.issued2010-08-
dc.identifier.citationEscitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression. 2010, 24 (8):1143-52 J. Psychopharmacol. (Oxford)en
dc.identifier.issn1461-7285-
dc.identifier.pmid20147575-
dc.identifier.doi10.1177/0269881109349835-
dc.identifier.urihttp://hdl.handle.net/10147/120517-
dc.description.abstractThe majority of currently marketed drugs contain a mixture of enantiomers; however, recent evidence suggests that individual enantiomers can have pharmacological properties that differ importantly from enantiomer mixtures. Escitalopram, the S-enantiomer of citalopram, displays markedly different pharmacological activity to the R-enantiomer. This review aims to evaluate whether these differences confer any significant clinical advantage for escitalopram over either citalopram or other frequently used antidepressants. Searches were conducted using PubMed and EMBASE (up to January 2009). Abstracts of the retrieved studies were reviewed independently by both authors for inclusion. Only those studies relating to depression or major depressive disorder were included. The search identified over 250 citations, of which 21 studies and 18 pooled or meta-analyses studies were deemed suitable for inclusion. These studies reveal that escitalopram has some efficacy advantage over citalopram and paroxetine, but no consistent advantage over other selective serotonin reuptake inhibitors. Escitalopram has at least comparable efficacy to available serotonin-norepinephrine reuptake inhibitors, venlafaxine XR and duloxetine, and may offer some tolerability advantages over these agents. This review suggests that the mechanistic advantages of escitalopram over citalopram translate into clinical efficacy advantages. Escitalopram may have a favourable benefit-risk ratio compared with citalopram and possibly with several other antidepressant agents.-
dc.language.isoenen
dc.subject.meshCitalopram-
dc.subject.meshDepressive Disorder, Major-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMeta-Analysis as Topic-
dc.subject.meshMolecular Conformation-
dc.subject.meshPubMed-
dc.subject.meshRandomized Controlled Trials as Topic-
dc.subject.meshSerotonin Uptake Inhibitors-
dc.subject.meshStereoisomerism-
dc.subject.meshTreatment Outcome-
dc.titleEscitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression.en
dc.typeArticleen
dc.contributor.departmentDepartment of Pharmacology, National University of Ireland, Galway, Ireland.en
dc.identifier.journalJournal of psychopharmacology (Oxford, England)en
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.